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inhibitor, has been shown to provide modest improvements in
lung function in patients with mild-to-moderate asthma, but its
efficacy in patients with moderate-to-severe asthma has not been
assessed. We hypothesized that this drug might provide benefit
if combined with montelukast, a leukotriene receptor
antagonist, in patients whose symptoms are uncontrolled by
inhaled corticosteroids and long-acting b-agonists.
Objective: We sought to examine the efficacy, safety, and mode
of action of the addition of roflumilast and montelukast versus
montelukast alone in patients with moderate-to-severe asthma.
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142(sequence AB) or placebo plus 10 mg of montelukast followed by
500 mg of roflumilast plus 10 mg of montelukast (sequence BA).
All patients had a diagnosis of bronchial asthma inadequately
controlled by at least a medium-dose inhaled corticosteroid plus
a long-acting b-agonist.
Results: The analysis of FEV1 change from baseline to week 4
showed a statistically significant and clinically meaningful
treatment difference of 100 mL for roflumilast plus montelukast
versus placebo plus montelukast. Also, improvements in patient-
reported outcomes and a reduction in urinary leukotriene E4 levels
were observed during roflumilast plus montelukast treatment
compared with placebo plus montelukast treatment. Adverse
events were consistent with the known safety profile of roflumilast.
Conclusion: The combination of roflumilast with montelukast
compared with montelukast alone improved lung function and
asthma control in patients with moderate-to-severe asthma and
deserves further study for this indication. (J Allergy Clin
Immunol 2016;138:142-9.)
Key words: Asthma, roflumilast, montelukast, phosphodiesterase 4
inhibitors
The recent American Thoracic Society (ATS)/European
Respiratory Society (ERS) Task Force on Severe Asthma has
defined severe asthma as asthma requiring Global Initiative for
Asthma step 4 or 5 treatment (high-dose inhaled corticosteroids
[ICSs] and long-actingb-agonists [LABAs] or leukotrienemodifier
or theophylline) for the previous year to prevent it from becoming
‘‘uncontrolled’’ or that remains ‘‘uncontrolled despite this ther-
apy.’’1,2Treatmentoptions for severe asthmaare limited and include
omalizumab,3 an anti-IgE antibody treatment indicated only in a
select phenotype of patients with high serum IgE levels, oral
corticosteroids, and, more recently, bronchial thermoplasty and
tiotropium.1-4 Although recommended, montelukast is not
approved for patients with severe asthma in some countries, and
there is little evidence from prospective trials supporting the
efficacy of leukotriene modifiers and theophylline added to other
controllers, such as a high-dose ICS and LABA at steps 4 and 5.1,2,5
Current research in asthma is focused on the development of
treatments that target specific components of airway inflamma-
tion,3 and results with anti–IL-4, anti–IL-5, and anti–IL-13
treatments are promising.1,6,7 However, these treatments are
likely to be suitable only for patients with well-defined endotypes
of disease, and there might be a role for combining different
classes of treatment, including those that are not restricted by
phenotype. Recognized phenotypes in asthmatic patients based
on sputum examination are eosinophilic (usually associated
with TH2-driven pathways), neutrophilic (or granulocytic), and
paucicellular.1,8 The Severe Asthma Research Program recog-
nized patients with the mixed granulocytic phenotype as having
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BATEMAN ET AL 143Abbreviations usedACQ: Asthma Control QuestionnaireAE: Adverse eventANCOVA: Analysis of covarianceATS: American Thoracic SocietyBMI: Body mass indexCOPD: Chronic obstructive pulmonary diseaseC-SSRS: Columbia Suicide Severity Rating ScaleERS: European Respiratory SocietyFEF25-75%: Forced expiratory flow between 25% and 75% of forced
vital capacityFENO: Fraction of exhaled nitric oxideFVC: Forced vital capacityICS: Inhaled corticosteroidIVRS: Interactive voice response systemLABA: Long-acting b-agonistLS: Least squareLTE4: Leukotriene E4
MAP: Multi Analyte ProfilePDE-4: Phosphodiesterase 4PEF: Peak expiratory flowSABA: Short-acting b-agonistTEAE: Treatment-emergent adverse eventmore severe disease (lowest lung function, most symptoms, and
higher health care use) and greater corticosteroid refractoriness.8
This heterogeneity provides the basis for combining treatments
that target different mechanisms, including some that can also
influence neutrophils.
The selective inhibitor of phosphodiesterase 4 (PDE-4),
roflumilast, is currently approved for use in patients with chronic
obstructive pulmonary disease (COPD) in several countries.
Inhibition of PDEs leads to an increase in intracellular cAMP
levels and suppression of inflammatory responses.9,10 In patients
with mild asthma, roflumilast has been shown to inhibit asthmatic
reactions to antigens,11,12 reduce sputum eosinophil and
neutrophil counts,12,13 and be effective in patients with
exercise-induced asthma.14 Efficacy has also been demonstrated
in patients with mild-to-moderate asthma.15 In patients with
COPD, it is prescribed as an oral once-daily maintenance
treatment (500 mg) and indicated as add-on treatment (to
bronchodilator treatment with or without ICSs) for patients with
severe and very severe COPD associated with chronic bronchitis
and a history of frequent exacerbations.16-18
Using a crossover study design, we set out to examine the
potential of combining roflumilast and montelukast, anti-
inflammatory treatments with different modes of action,
compared with montelukast and a placebo in patients with
uncontrolled asthma receiving at least a moderate dose of ICS
plus LABA. In addition to assessing the safety and clinical end
points of pulmonary function, symptoms, and asthma control, we
explored selected serum and urinary biomarkers to cast light on
the potential mode of action of these treatments.METHODS
Patients
We enrolled patients aged 18 or more years who had asthma of at least
6 months’ duration that was inadequately controlled (Asthma Control
Questionnaire [ACQ-7] score >_1.5) despite at least a medium-dose ICS at a
stable dose (fluticasone propionate, >_250 mg/d or equivalent) plus LABAtherapy during the 4 weeks before screening. Additional requirements were a
prebronchodilator FEV1 of greater than 55% but 85% or less of predicted
value at the screening and at least a 12% and 200-mL improvement in FEV1
after inhalation of a short-acting b-agonist (SABA) recorded in the previous
12months or at screening. Patients were excluded if theywere current smokers
or had a smoking history of 10 or more pack years or had experienced a severe
asthma exacerbation or a lower respiratory tract infection within 4 weeks of
the baseline visit. A full list of inclusion/exclusion criteria and prohibited
concomitant medications is provided in Appendices E1 and E2 in this article’s
Online Repository at www.jacionline.org.
During the study, salbutamol (100 mg per puff) administered through a
pressurized metered-dose inhaler was used as as-needed reliever medication.
All patients continued to receive their current maintenance ICS and LABA
therapy at a constant dose throughout the study. Other controller therapies
were not permitted.
Study design
This was a phase 2, randomized, placebo-controlled, multiple-dose,
2-sequence crossover study, with two 4-week treatment periods separated
by a 4-week washout period (Fig 1). A 4-week crossover design was chosen
primarily to reduce between-patient variability and minimize the required
number of patients. The treatment duration was limited to 4 weeks to reduce
potential influences of season and baseline health, and based on previous
studies with these drugs, this was long enough to demonstrate potential
efficacy. The study was conducted between January and October 2013 at 15
sites in Germany, Hungary, and South Africa. During the double-blind
treatment phase, patients were randomly assigned to 1 of 2 treatment
sequences. The method of randomization is described in the Methods section
in this article’s Online Repository at www.jacionline.org.
Study end points
The primary efficacy end point was change in prebronchodilator FEV1 from
baseline and the end of thewashout period toweek 4 (the end of each treatment
period) measured in the clinic by using the same spirometer for each patient
throughout the study according to ATS/ERS consensus guidelines for
pulmonary function testing.19 Secondary efficacy end points were change in
prebronchodilator forced vital capacity (FVC), forced expiratory flow between
25% and 75% of forced vital capacity (FEF25-75%), and peak expiratory flow
(PEF) at the same time points: morning PEF was obtained from home
measurements, and daytime and nighttime asthma symptoms were recorded
by using an ePEF meter.19 Asthma control was measured by using the ACQ-7
(see the Methods section in this article’s Online Repository).20 Exploratory
end points included total and differential WBC counts, a panel of 46 inflamma-
tory mediators in serum measured by using the Human Inflammation
Multi-Analyte Profile (MAP) detection panel (Myriad RBM kit; Rules-Based
Medicine, Austin, Tex), symptoms, as-needed SABA use, ACQ-7 scores, and
urinary leukotriene E4 (LTE4) levels.
21,22 In a post hoc responder analysis the
number of patients who achieved an ACQ-7 score decrease of 0.5 or greater
was also summarized. Additional exploratory end points included asthma
exacerbations and dropouts caused by adverse events (AEs).
In 14 (21.9%) patients differential cell counts and inflammatory biomarkers
in induced sputum, fraction of exhaled nitric oxide (FENO), and FENO/LTE4
ratio were measured by using the recommended methods.19 The analysis of
inflammatory mediators in dithiothreitol-treated sputum supernatants was
performed with the Human Inflammation MAP detection panel (Myriad
RBM kit; Rules-Based Medicine; see the Methods section in this article’s
Online Repository).22
Safety
Safety monitoring included AEs, laboratory tests, measurement of body
mass index (BMI) and vital signs, and electrocardiography. Safety assessment
continued for 30 days after the active treatment period. The protocol was
approved by relevant health authorities and local institutional review boards.
The study was conducted according to Good Clinical Practices Guidelines and
theDeclaration of Helsinki. All patients providedwritten informed consent for
study participation.
FIG 1. Schematic of the crossover study design: 2- to 4-week screening period, followed by two 4-week
double-blind treatment periods separated by a washout period of 4 weeks. A final visit took place 7 to
21 days after the second treatment period. QD, Once daily.
J ALLERGY CLIN IMMUNOL
JULY 2016
144 BATEMAN ET ALStatistical analysis
The primary end point was analyzed with an analysis of covariance
(ANCOVA) model including treatment, sequence, period, and baseline FEV1
measurement as fixed factors and patient nested in sequence as a random
factor. Secondary end points (change from baseline) determined by using
spirometry (prebronchodilator FVC, FEF25-75%, and PEF) were analyzed
with similar ANCOVA models. Least square (LS) means for each treatment
and the estimate of the treatment difference together with the corresponding
95% CI, as well as 2-sided P values, were calculated. Reporting of efficacy
and safety end points was descriptive (frequency and percentages for
categorical data and means, SDs, medians, minimums, and maximums for
continuous data) by study visit.
The sample size of 30 in each sequence group provided 60% power to
detect a difference in means between treatment groups of 100 mL (assuming
that the SD of differences was 330 mL) by using a 2-group t test for the
difference of means in the 23 2 crossover design. All CIs and statistical tests
were 2-sided and performed at the .05 significance level (unless otherwise
specified) and considered exploratory inferential analyses. No adjustment
was made for multiple comparisons. SAS software (version 9.2; SAS Institute,
Cary, NC) was used for statistical analyses (see the Methods section in this
article’s Online Repository for full statistical analysis details).RESULTS
Of 103 patients screened, 64 (mean age, 50.1 years; 64.1%
women) were randomized. The mean prebronchodilator FEV1
was 69.6% and 72.7% of predicted value, FEV1 reversibility
was 20.5% and 18.2% at baseline, and the ACQ-7 score was
2.16 and 2.30 in the 2 sequence groups, respectively (Table I).
Baseline asthma controller medications taken throughout the
study are listed in Table I. All patients were taking an ICS/LABA
combination fixed at a constant dose. Eighteen patients were
receiving a high daily dose of 800 mg budesonide or more;
however, doses were not recorded for 7 patients. Four patients
had protocol violations relating to concomitant medication use,
2 of which were due to the use of oral corticosteroids during
the study.Fifty-seven (89.1%) patients completed all planned study
visits. Seven patients discontinued study drug treatment and did
not attend all planned study visits, 3 (1 while receiving roflumilast
plusmontelukast and 2while receiving placebo plusmontelukast)
caused by treatment-related AEs and 4 for ‘‘other reasons’’
(Fig 2).
A summary table of additional spirometic variables and their
mean baseline values on days 1 and 56 are listed in Table E1 in this
article’s Online Repository at www.jacionline.org.Pulmonary function
The 2 treatment sequences, AB (roflumilast plus montelukast
and then placebo plus montelukast) and BA (placebo plus
montelukast and then roflumilast plus montelukast), were
evaluated separately.Prebronchodilator FEV1
The mean baseline FEV1 values on day 1 at the start of period 1
for the placebo plusmontelukast and roflumilast plus montelukast
groups were 2.177 and 1.929 L, respectively. Mean baseline
values on day 56 at the start of period 2 for the placebo plus mon-
telukast and roflumilast plus montelukast groups were 1.899 and
2.144 L, respectively.
The change from baseline toweek 4 in prebronchodilator FEV1
was higher in the roflumilast plus montelukast group than in the
placebo plus montelukast group in both periods 1 and 2 (Fig 3,
A). By the end of period 1, there was an 81-mL difference in
FEV1 mean change from baseline in favor of roflumilast plus
montelukast relative to placebo plus montelukast, and by the
end of period 2, the difference was 171 mL.
Based on the ANCOVA analysis, the adjusted mean change
from baseline to week 4 in prebronchodilator FEV1 was higher in
the roflumilast plus montelukast group than in the placebo plus
TABLE I. Demographics and baseline characteristics
Characteristic
Sequence AB
(roflumilast 1 montelukast/
placebo 1 montelukast [n 5 32])
Sequence BA
(placebo 1 montelukast/
roflumilast 1 montelukast [n 5 32])
Female sex, no. (%) 21 (65.6) 20 (62.5)
Age (y)
Mean (SD) 50.3 (13.8) 50.0 (14.1)
>_65, no. (%) 5 (15.6) 5 (15.6)
BMI (kg/m2), mean (SD) 29.53 (7.105) 30.06 (5.605)
Smoking history, no. (%)
Never smoked 22 (68.8) 21 (65.6)
Exsmoker 10 (31.3) 11 (34.4)
Cigarette pack years (exsmoker), mean (SD)* 4.8 (2.39) 6.3 (3.32)
Country, no. (%)
South Africa 16 (50.0) 11 (34.4)
Germany 8 (25.0) 12 (37.5)
Hungary 8 (25.0) 9 (28.1)
Spirometric baseline parameters, mean (SD)
Predose prebronchodilator FEV1 (L) n 5 32
1.929 (0.717)
n 5 32
2.177 (0.708)
Predose prebronchodilator FEV1 (% predicted) n 5 32
69.6 (15.99)
n 5 32
72.7 (16.01)
Postbronchodilator FEV1 (L) n 5 29
2.263 (0.694)
n 5 26
2.405 (0.659)
FEV1 reversibility increase (mL) n 5 32
356.3 (178.1)
n 5 32
335.0 (207.5)
FEV1 reversibility increase (%) n 5 32
20.5 (12.9)
n 5 32
18.2 (10.4)
ACQ-7 score, mean (SD) 2.16 (0.72) 2.30 (0.76)
Baseline medication (ICS/LABA), no. (%) n 5 32 n 5 32
Fluticasone propionate/salmeterol xinafoate 14 (43.75) 11 (34.38)
Fluticasone propionate/formoterol fumarate 0 1 (3.13)
Budesonide/formoterol fumarate 14 (43.75) 14 (43.75)
Budesonide/salmeterol xinafoate 2 (6.25) 2 (6.25)
Beclomethasone dipropionate/formoterol fumarate 2 (6.25) 2 (6.25)
A, Roflumilast (500 mg once daily) plus montelukast (10 mg once daily); B, placebo plus montelukast (10 mg once daily).
*Cigarette pack years are calculated as follows: ([Number of cigarettes per day/20] 3 Number of years of smoking), where 1 pipe/cigar corresponds to 5 cigarettes.
Data on ICS/LABA combinations before study start for 2 patients were not recorded.
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icant difference of 100 mL (SE, 39 mL).FVC
The mean baseline FVC values on day 1 (period 1) for the
placebo plus montelukast and roflumilast plus montelukast
groups were 3.307 and 3.000 L, respectively, and on day 56
(period 2), these values were 2.942 and 3.259 L for the placebo
plus montelukast and roflumilast plus montelukast groups,
respectively. For the 2 periods combined, the mean change in
FVC from baseline to week 4 was not significantly different
between the roflumilast plus montelukast and placebo plus
montelukast groups (120 vs 60mL, respectively;P5 .129). How-
ever, viewed as individual periods, the change from baseline to
week 4 in FVC for period 2 for the roflumilast plus montelukast
groupwas higher than that for the placebo plusmontelukast group
(difference of 114 mL; Fig 3, B).Other lung function variables (PEF and FEF25-75%)
In the analysis of PEF, the mean baseline values on day 1
(period 1) for the placebo plus montelukast and roflumilast plus
montelukast groups were 307.85 and 292.43 L/min, and on day 56(period 2), these values were 285.44 and 350.15 L/min for the
placebo plus montelukast and roflumilast plus montelukast
groups, respectively. The LS mean change in in-clinic prebron-
chodilator PEF from baseline to week 4 was 15.1 L/min for
roflumilast plus montelukast and 7.9 L/min for placebo plus
montelukast, respectively (not statistically significant). However,
the analysis of morning PEF change from baseline to week 4
measured at home showed a statistically significant LS mean
difference of 13.6 L/min for roflumilast plus montelukast versus
placebo plus montelukast. Change from baseline in FEF25-75% to
week 4measured at clinic visits provided similar results (Fig 3,C;
see Table E2 in this article’s Online Repository at www.
jacionline.org).ACQ and symptom scores
Small improvements in the overall ACQ-7 and ACQ-5 scores
were observed with both treatments, but the difference between
them was not statistically significant (LS mean difference of
20.17 in favor of roflumilast plus montelukast for both scores).
During period 1, the mean decrease in ACQ-7 scores (improve-
ment) was 0.29 with placebo plus montelukast and 0.37 with
roflumilast plus montelukast, and during period 2, the mean
decrease was 0.22 (placebo plus montelukast) and 0.49
FIG 2. Disposition of patients. A, Roflumilast (500 mg) plus montelukast (10 mg) once daily (QD). B, Placebo
plus montelukast (10 mg) QD.
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achieving the minimal clinically important difference for an
ACQ-7 of 0.5. In a post hoc analysis a larger number of patients
achieved an ACQ-7 score decrease of 0.5 or greater while
receiving roflumilast plus montelukast (15 patients) compared
with those receiving placebo plus montelukast (8 patients).
Treatment differences (roflumilast plus montelukast vs placebo
plus montelukast) in asthma symptom scores were 20.09
(nighttime) and 20.21 (daytime), with the daytime symptom
treatment difference being statistically significant. Similarly, it
was observed that overall, patients used reliever medication less
often while receiving roflumilast plus montelukast than while
receiving placebo plus montelukast.Exacerbations
During the study (days 1-84 or early termination), 4 patients
treated with roflumilast plus montelukast and 8 patients treated
with placebo plus montelukast experienced moderate-to-severe
asthma exacerbations. The exacerbation events tended to be of
shorter duration in the roflumilast plus montelukast group (mean,
10.0 days) compared with those in the placebo plus montelukast
group (mean, 13.3 days). None of these events was considered a
serious AE, and therewere no discontinuations because of asthma
exacerbations.Eosinophils and neutrophils in peripheral blood and
biomarkers in serum
There was no significant change in the number and percentages
of eosinophils (see Table E3 in this article’s Online Repository atwww.jacionline.org) or neutrophils (data not shown) in peripheral
blood during either treatment period. Similarly, no significant
changes in serum inflammatory mediators were observed.Urinary LTE4
Initial mean values for urinary LTE4 were similar at baseline in
the 2 sequence groups (228 and 247 ng/mg, respectively). In the
group that received roflumilast plus montelukast during period
1 (treatment sequence AB in Fig 4), urinary LTE4 values
decreased by day 28 and remained low during period 2, when
patients were receiving placebo plus montelukast. In the second
sequence group (treatment sequence BA in Fig 4) that received
placebo plus montelukast during period 1, values remained un-
changed during period 1, appeared to increase during the washout
period to approximately twice the upper limit of normal before
the start of period 2, and decreased towithin the normal range dur-
ing period 2 while receiving roflumilast plus montelukast (Fig 4).Sputum inflammatory cells and biomarker and FENO
values
In the substudy of 14 patients, results for each parameter were
obtained on too few patients to permit analysis: sputum data from
between 1 and 6 patients and FENO values from 1 to 9 patients.Safety
The mean durations of exposure for sequence AB (83.1 days)
and sequence BA (78.4 days) were similar. Forty-one (64.1%)
patients reported at least 1 treatment-emergent adverse event
FIG 4. Changes in urinary LTE4 values (SD) during treatment sequences AB
(n 5 32) and BA (n 5 32). A, Roflumilast (500 mg once daily) 1montelukast
(10 mg once daily); B, placebo plus montelukast (10 mg once daily). Mean
(SD) values were measured at baseline period 1, day 28, baseline period 2,
and day 84.
FIG 3. A,Mean (SD) change from baseline in prebronchodilator FEV1 (in liters) in treatment periods 1 and 2
(full analysis set). B,Mean (SD) change from baseline to week 4 in FVC in treatment periods 1 and 2. C,Mean
change from baseline to week 4 in prebronchodilator PEF (in liters). D, Improvement (reduction) in ACQ-7
score (mean change from baseline) by visit comparing montelukast plus placebo and montelukast plus
roflumilast. MCID, Minimal clinically important difference.
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33.9% during placebo plus montelukast treatment. The majority
were mild or moderate in intensity (see Table E4 in this article’s
Online Repository at www.jacionline.org). The most frequent
TEAE was headache (in 8.2% of patients receiving roflumilast
plus montelukast; see Table E5 in this article’s Online Repository
at www.jacionline.org). Three patients discontinued the study
drug prematurely because of a TEAE, 1 each with neuralgia(during roflumilast plus montelukast treatment), abdominal
pain, and pneumonia (during placebo plus montelukast treat-
ment). There were no serious AEs or deaths.DISCUSSION
This phase 2 proof-of-concept study is the first to formally
evaluate combining a PDE-4 inhibitor with a leukotriene modifier
in patients with asthma of any severity. It focused on patients with
moderate-to-severe asthma, which is the group with greatest
clinical need for whom combinations of treatments are recom-
mended. Recent experience with anti-IgE, anti–IL-5, anti–IL-4,
and anti–13 treatments has confirmed that this group of patients
respond to targeted anti-inflammatory treatments. Because both
roflumilast and montelukast have anti-inflammatory properties
but with different modes of action, it was hypothesized that
combining them might be effective without the need for prior
inflammatory phenotyping of patients.
The results of the study provide evidence that adding
roflumilast to the background therapy of ICS/LABA plus
montelukast results in improvements across a range of outcomes,
including lung function, symptoms, and asthma control, as well as
in urinary LTE4 levels. In keeping with previous reports,
1,2 mon-
telukast alone in these patients with moderate-to-severe asthma
did not appear to have much effect and achieved only small
nonsignificant improvements. When roflumilast was added to
montelukast, both statistically and possibly clinically significant
improvements were observed. The overall difference in mean
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relative to placebo plus montelukast was 100 mL (95% CI,
0.0219-0.1795; P 5 .013), and by the end of the second period,
the difference was 171 mL. An interesting and surprising finding
was the greater response both in terms of lung function and
ACQ-7 (and ACQ-5) scores to the combination therapy when
administered in the second period. There appeared to be a
carryover effect from period 1 through a 4-week washout period
to period 2, suggesting that the benefit of the combination
required more time to develop and that pretreatment (‘‘priming’’)
with montelukast for 4 weeks had occurred. Given the
pharmacodynamics of montelukast, there is no likelihood of
continued activity during the washout period, nor is there
evidence that its effect is potentiated when reintroduced after
having stopped montelukast for 4 weeks (here, in the company
of roflumilast). Because neither treatment is a bronchodilator, it
seems likely that the improvements in lung function are the
consequence of their anti-inflammatory properties.9,13,23 Further-
more, although the efficacy of roflumilast alone in this setting was
not tested because there was little additional benefit during the
second treatment period when montelukast alone was used, it
appears that roflumilast played the dominant role in this
combination.
The improvements in FEV1 were accompanied by changes
in FVC and FEF25-75% values and associated with improve-
ments in home-monitored morning PEF, daytime symptoms,
and asthma control scores (ACQ-7). At study’s end, although
not statistically significant between treatments, the mean
overall improvement (reduction) in ACQ-7 score from baseline
in patients receiving montelukast plus roflumilast in period 2
almost achieved the minimal clinically important difference
for an ACQ-7 score of 0.5, a surprising result given the
difficulty of achieving this in studies of add-on therapy in
asthmatic patients.24 A post hoc responder analysis confirmed
a decrease of 0.5 or greater in ACQ-7 score in only 1 of the
2 treatment periods with roflumilast plus montelukast (15
patients) compared with 8 patients receiving placebo plus mon-
telukast. Reliever medication use was also lower while patients
were taking roflumilast plus montelukast than while taking pla-
cebo plus montelukast.
The exploratory analysis of markers of inflammation in blood,
urine, and sputum provided limited information. The most
striking result of this novel combination of anti-inflammatory/
antiallergy drugs was the reduction in urinary LTE4 levels not
seen with montelukast alone and occurring only when roflumilast
was added. The reason for this is not apparent. Urinary LTE4 is a
biomarker of total body cysteinyl leukotriene production, and
levels are higher in patients with moderate-to-severe asthma
and reduced by anti-inflammatory treatments, such as ICSs and
leukotriene receptor antagonists.25 However, environmental
factors, such as exposure to tobacco smoke, can also increase
urinary LTE4 levels, and treatments vary in their relative efficacy
in reducing LTE4 levels in different patients. For example, in
children with uncontrolled asthma receiving step 3 treatment,
an increased LTE4/FENO ratio predicts a more favorable response
to montelukast.26 In the current study it is of interest that urinary
LTE4 baseline levels were high in spite of current ICS use,
suggesting that the patients in this study were relatively refractory
to ICSs. ICSs have been shown to reduce urinary LTE4 levels.
26
Surprisingly, montelukast alone also seemed ineffective in
reducing urinary LTE4 levels, and if anything, levels increasedduring montelukast treatment and only decreased when
roflumilast was added. No changes in numbers of circulating
neutrophils, eosinophils, or other leukocytes were noted during
the study, and no other significant trends in inflammatory markers
were evident.
Furthermore, apart from headache in a small percentage of
patients, there were no safety concerns from the addition of
roflumilast to montelukast, and the reported AEs were consistent
with the known profile from roflumilast in its currently approved
indication for COPD. Discontinuation because of side effects was
similar between treatment arms. Experience with roflumilast in
both asthmatic patients and patients with COPD confirms that
symptoms of headache and gastrointestinal tract disturbance
(loose stools) tend to resolve within weeks with continued use.15
The current study was too short to assess this, but gastrointestinal
symptoms were not prominent.
The potential of interactions between montelukast and
roflumilast as an explanation for the enhanced effect obtained
with both needs to be considered because both drugs share a
common metabolic pathway through cytochrome P450 3A.
B€ohmer et al27 reported that the pharmacokinetics of roflumilast
and roflumilast N-oxide (its active metabolite) in steady state
remain unchanged when montelukast is coadministered at steady
state and that both drugs are well tolerated. Thus no dose
adjustment for either drug is necessary when roflumilast and
montelukast are coadministered.
A weakness of our study is its small size and short duration,
with limited statistical power (although increased by its crossover
design) to provide reliable estimates of the benefits of
adding roflumilast to montelukast. However, given the
consistency of effects across different end points, the results
justify larger studies powered to examine the clinical efficacy of
the combination.
The strengths of the study are the well-defined population
(representing patients with moderate-to-severe asthma with a
clinical need for more controllers) and the inclusion of
biomarkers to examine potential mechanisms of action. The
latter has at least 1 result that encourages further mechanistic
studies to explore the interactions of these 2 drugs on
inflammatory pathways in asthmatic patients. Although
unexpected, the effect of the combination treatment on urinary
LTE4 levels should be explored both as an outcome and poten-
tially as a biomarker for selecting patients for this combination.
The potential of this treatment for reducing asthma exacerbations
also deserves study.
In conclusion, we have demonstrated in a 2-period crossover
study that the combination of roflumilast with montelukast in
patients with uncontrolled asthma in spite of a moderate-dose
ICS and a LABA is associated with improvements in lung
function, asthma control (measured by the ACQ-7), and
symptoms and that the combination is well tolerated. The
results lend support to the concept of combining anti-
inflammatory drugs with different mechanisms of action in
patients with more severe forms of asthma and for exploring
currently available drugs approved for use in Global Initiative
for Asthma step 4 and higher treatment guidelines alongside
newer and more expensive biological agents currently in
development.
Medical writing support was provided by Caroline Loder of Synergy Vision
(United Kingdom) and funded by Takeda.
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d The PDE-4 inhibitor roflumilast and the leukotriene mod-
ifier montelukast provide additive benefit in patients with
moderate-to-severe asthma.
d Combination treatment, but not montelukast alone,
reduced urinary LTE4 levels.REFERENCES
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METHODS
ACQ
Questions were based on recall of the previous 7 days and included
breathlessness, nocturnal waking, symptoms on waking, activity limitation,
wheeze, frequency of SABA use, and prebronchodilator FEV1 percent
predicted. All 7 items are scored on a 7-point scale without weighting (0,
good control; 6, poor control), and the overall score (range, 0-6) is the
mean of the responses. The ACQ has been validated against quality of
life and physician global assessment, and the minimal important
difference is 0.5. The optimal cut point for ‘‘well controlled’’ using the
Gaining Optimal Asthma Control classification is less than or equal to 0.75,
and a value of greater than or equal to 1.50 confirms ‘‘not well-controlled’’
asthma.
Inflammatory markers in induced sputum
Sputum was induced in a substudy of 14 patients at specialized sites with
experience in sputum induction and processing. Centralized hands-on training
sessions in sputum collection, handling, and processing was provided to
ensure adequate quality and consistency of sputum samples between
investigational sites. Sputum induction was performed in accordance with
the review and recommendation by the ERS Task Force 2002. Postbroncho-
dilator FEV1 was determined before sputum induction. Sputum induction was
stopped if FEV1 decreased by 20% or greater of postbronchodilator baseline.
Sputum assessments were not performed if, for medical reasons, patients were
unable to produce sputum at a scheduled visit.
Sputum samples were collected and initially processed at the study sites to
prepare the cellular component on a cytospin and isolate the fluid phase
(supernatant). Total cell counts and cell viability were assessed and reported
during sputum processing. Sputum supernatants were stored in a freezer at
2808C until final analysis. Cytospin preparations and supernatants were
assessed at a specialized laboratory. Differential cell counts on stained
cytospin preparations were expressed both as percentages and total cell
numbers for neutrophils, macrophages, eosinophils, lymphocytes, and
epithelial cells, as recommended by ATS/ERS 2009.
Randomization
Randomization was determined by using an interactive voice response
system (IVRS) with a 1:1 randomization scheme. Treatments were received in
2 different sequences: AB (500mg of roflumilast followed by placebo) and BA
(placebo followed by 500 mg of roflumilast). Patients received 10 mg of
montelukast once daily as open-label treatment in combination with either
placebo or roflumilast in both treatment periods.
Treatment period 1 (day 1 through day 28)
At baseline (visit 2/day 1), after study eligibility was confirmed, patients
were randomized by using the IVRS, dispensed study drug, and instructed to
take the study drug once daily in the evening.
Before the first dose of study drug, the following procedures/assessments
were performed during this visit: changes in prior medications, changes in
concomitant medications, vital signs, weight, BMI, clinical laboratory tests,
serum and urine pregnancy tests, pregnancy avoidance, substance use,
inflammatory markers in blood, urinary LTE4 level, Columbia Suicide
Severity Rating Scale (C-SSRS), pulmonary function tests, IVRS access, in-
flammatorymarkers in induced sputum and exhaled FENO (only in selected pa-
tients), ACQ, ePEF meter data/diary review, AE assessment, and salbutamol
prescription, if needed. Patients returned to the study site at visit 3 (day
28 6 2 days) to return unused study drug and undergo the following proce-
dures/assessments: changes in concomitant medications, vital signs, weight,
BMI, urine pregnancy test, pregnancy avoidance, substance use, inflammatory
markers in blood, urinary LTE4 level, C-SSRS, pulmonary function tests, in-
flammatorymarkers in induced sputum and exhaled FENO (only in selected pa-
tients), ACQ, ePEF meter data/diary review, AE assessment, study drug
compliance, and salbutamol prescription, if needed.
Treatment period 2 (day 56 through day 84)
At the conclusion of the washout period, patients returned to the study site
at visit 4 (day 56 6 2) and were dispensed study drug for their second
treatment sequence. The following procedures/assessments were performed
during this visit: changes in concomitant medications, vital signs, weight,
BMI, urine pregnancy test, pregnancy avoidance, substance use, inflammatory
markers in blood, urinary LTE4 level, C-SSRS, pulmonary function tests,
inflammatory markers in induced sputum and exhaled FENO (only in selected
patients), ACQ, ePEF meter data/diary review, AE assessment, study drug
compliance, and salbutamol prescription, if needed.
At the end of the study treatment phase (or upon early withdrawal from the
study), patients returned to the study site at visit 5 (day 846 2 days) to return
unused study drug and undergo the following procedures/assessments:
changes in concomitant medications, physical examination, vital signs,
weight, BMI, clinical laboratory tests, serum pregnancy test, pregnancy
avoidance, urinalysis, electrocardiography, substance use, inflammatory
markers in blood, urinary LTE4 level, C-SSRS, pulmonary function tests,
IVRS access, inflammatory markers in induced sputum and exhaled FENO
(only in selected patients), ACQ, ePEF meter data/diary review, AE assess-
ment, study drug compliance, and salbutamol prescription, if needed.
Statistical analysis
Primary efficacy end point. The primary end point was analyzed
by using an ANCOVA model adapted for the crossover design.
The dependent variable was change from baseline and end of the
washout period to week 4 measurement of the respective treatment
period. For patients who did not complete the week 4 visit, the last
postrandomization measurement of predose (trough) prebronchodilator
FEV1 in the respective treatment period was used. The following fixed
factors and covariates were included in the model: treatment, sequence,
period, and baseline FEV1 measurement of the respective treatment period.
Additionally, the model contained a random factor patient nested in
sequence (the between-patient error) and a random residual error term (the
within-patient error).
The LS means for each treatment and the estimate of the treatment
difference together with the corresponding 95% CI, as well as 2-sided
P values, were presented. In addition, predicted values were summarized.
Comparability of treatment groups and sequences was not proved formally
by using methods of statistical hypothesis testing but was examined with
description of baseline characteristics. No formal assessment of a carryover
effect was performed.
Secondary efficacy end points. The secondary end points
(change from baseline) from spirometry (prebronchodilator FVC, FEF25-75%,
and PEF) were analyzed by using an ANCOVA model adopted for the
crossover design, including independent factors and covariates in analogy to
the primary model. All lung function variables were summarized in a
descriptive manner by treatment and study visit (randomization, week 4,
week 8, and week 12). In addition, predicted values were summarized.
Exploratory end points. Weekly average of morning PEF from
home measurements, asthma symptom scores (daytime and nighttime asthma
symptom score), and use of reliever medication (puffs per week) were
calculated by using the nonmissing daily records from the last 7 days of each
treatment period. The weekly average of the last 7 days before the first dose of
treatment period 1 and treatment period 2 was calculated as the baseline value
for the corresponding treatment period. The weekly average was analyzed by
using an ANCOVA model adopted for the crossover design, including
independent factors and covariates in analogy to the primary model.
Additionally, weekly average of morning PEF, asthma symptom scores, and
use of reliever medication were summarized in a descriptive manner by
treatment and study visit.
The ACQ score was analyzed by using an ANCOVAmodel adopted for the
crossover design, including independent factors and covariates similar to the
model of the primary efficacy end point. In post hoc analyses the number of
patients who achieved an ACQ-7 score decrease of 0.5 or greater was
summarized, and the overall ACQ-5 score was analyzed.
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Descriptive statistics were used to describe the following:
d SABA use;
d changes in total and differential WBC counts in blood (absolute
[cells/volume] and percentage);
d changes in concentration of individual inflammatory mediators
(based on Human Inflammation MAP; Rules-Based Medicine, using
Myriad RBM kit) in serum;
d changes in cellular composition of sputum, including neutrophils,
macrophages, eosinophils, lymphocytes, and epithelial cells, in a
substudy of patients; and
d changes in concentrations of individual mediators (based on
Human Inflammation MAP; Rules-Based Medicine, using
Myriad RBM kit) in the sputum supernatant in a substudy of
patients: changes in FENO values, FENO/LTE4 ratios, and urinary
LTE4 levels.
APPENDIX E1. EXCLUSION/INCLUSION CRITERIA
Patients meeting any of the following criteria were excluded
from study enrollment:
1. The patient has received any investigational compound
within 30 days before the start of the clinical study or
participated in the active treatment phase of another clin-
ical study in which a persisting pharmacodynamic effect
of the study treatment of that clinical study could not be
excluded (ie, the patient is well into a treatment-free
follow-up phase).
2. The patient participated in another clinical study during
the current study.
3. The patient was an immediate family member, study site
employee, or in a dependent relationship with a study site
employee who was involved in conducting this study (eg,
spouse, parent, child, and sibling) or might have con-
sented under duress.
4. The patient had a severe asthma exacerbation that had not
resolved 4 weeks before visit 1 (defined by the need for
oral or parenteral glucocorticosteroid intake for at least
3 days and/or hospitalization or emergency department
visit with the need for oral or parenteral corticosteroid
use).
5. The patient had a lower respiratory tract infection that
had not resolved 4 weeks before visit 1.
6. The patient had a diagnosis of COPD (based on Global
Initiative for Chronic Obstructive Lung Disease criteria)
and/or other relevant forms of lung disease (eg, history
of primary bronchiectasis, cystic fibrosis, idiopathic
[pan] bronchiolitis or bronchiolitis obliterans, broncho-
pulmonary allergic aspergillosis, Churg-Strauss syn-
drome, paradoxical vocal cord closure, lung resection,
lung cancer, interstitial lung disease [eg, fibrosis, sili-
cosis, and sarcoidosis], or active tuberculosis) that might
have interfered with evaluation of a treatment response.
7. The patient was participating in a pulmonary rehabilita-
tion program or completed a pulmonary rehabilitation
program within 3 months before visit 1.
8. The patient had, in the judgment of the investigator, clin-
ically significant abnormal laboratory values (hematology
or biochemistry) at screening, suggesting an undiagnosed
disease requiring further clinical evaluation.
9. The patient had severe neuropsychiatric or neurological
disorders (eg, history of depression associated with
suicidal thinking, suicidal ideation, or behavior).
10. The patient had congestive heart failure of severity grade
III or IV according to the New York Heart Association.
11. The patient had symptomatic ischemic heart disease
(angina pectoris).
12. The patient had hemodynamically significant cardiac ar-
rhythmias or heart valve deformations.
13. The patient had liver impairment, which was defined as
Child-Pugh B/C and/or active viral hepatitis. Verified
laboratory results needed to fulfill the Child-Pugh B/C
classification (eg, international normalized ratio and
albumin levels) were not required unless there was a
verified reason to do so in individual cases and only after
consultation with the medical monitor.
14. The patient had severe immunologic disease (eg, multiple
sclerosis, systemic lupus erythematosus, or progressive
multifocal leukoencephalopathy) or known infection
with HIV.
15. The patient had severe acute infectious disease (eg, tuber-
culosis or acute hepatitis).
16. The patient had any diagnosis of a malignant disease
(other than basal or squamous cell carcinoma) within
5 years before visit 1.
17. The patient had a history of smoking within 1 year of visit
1 and a smoking history of 10 pack years or greater.
18. The patient had a history of drug abuse (defined as illicit
drug use) or alcohol abuse (defined as regular or daily
consumption of >2 alcoholic drinks per day) within
1 year before visit 1.
19. The patient had a history of clinically significant allergies or
idiosyncrasies to roflumilast, montelukast, or any inactive
ingredient(s) of these products (eg, rare hereditary problems
of galactose intolerance, the Lapp lactase deficiency,
glucose-galactose malabsorption, or phenylketonuria).
20. The patient had known highly unstable asthma defined by
severe bronchoconstriction after bronchoprovocation with
isotonic saline.
21. The patient was a women of childbearing potential who
was not willing to use acceptable contraceptive methods,
such as hormonal contraceptives (oral, injection, or
implant) or intrauterine contraceptive devices, or who
started such methods less than 2 months before visit 1
or who was not willing to use a double-barrier method
of contraception (diaphragm plus condom) or to remain
abstinent throughout the study.
22. The patient was a women who was pregnant or lactating
or intending to become pregnant before, during, or within
1 month after participating in this study or intending to
donate ova during such time period.
23. The patient was required to take excluded medication.
APPENDIX E2. EXCLUDED MEDICATIONS AND
TREATMENTS
The following medications were not allowed throughout the
study and were withdrawn throughout enrollment and before visit
1, where specified:
d oral and parenteral glucocorticosteroid maintenance
treatment (with the exception of oral and/or parenteral
glucocorticosteroids for the treatment of an asthma
exacerbation during the treatment periods);
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d ICSs or inhaled LABAs as monotherapy;
d any SABAs (with the exception of salbutamol supplied by
the sponsor);
d oral b-agonists;
d short- and long-acting anticholinergic agents (eg, ipra-
tropium or tiotropium);
d combination of anticholinergic agents with SABAs;
d theophylline monotherapy and/or derivatives (aminophyl-
line or diprophylline) or combinations thereof or any other
theophylline-containing products within 7 days before
baseline (visit 2);
d lipoxygenase inhibitors and leukotriene receptor antago-
nists (except montelukast) within 2 weeks before baseline
(visit 2);
d recombinant DNA-derived humanized IgE mAbs (omalizu-
mab) within 4 months before baseline (visit 2);
d use of other immunosuppressive medications within
3 weeks before baseline visit 2 (eg, cyclosporine, metho-
trexate, TNF-a receptor inhibitors or antibodies, gold, or
azathioprine);
d systemically administered b-receptor blockers, adenosine;
d strong CYP inducers (rifampin, phenobarbital, carbamaze-
pine, phenytoin, primidone, or phenylbutazone); and
d strong CYP3A4, CYP1A2, or dual inhibitors that inhibit
both CYP3A4 and CYP1A2 simultaneously (protease
inhibitors including atazanavir, indinavir, nelfinavir, ritona-
vir, and saquinavir, macrolide antibiotics including erythro-
mycin, clarithromycin, and telithromycin, azole antifungals
[including itraconazole and ketoconazole], nefazodone, flu-
oroquinolones [including ciprofloxacin and fluvoxamine],
enoxacin, or cimetidine).
All other concomitant medications (including over-the-
counter medications, herbal medications, and complementary
therapies) were required to remain symptom stability between
screening and completion of the study unless modification was
essential for the management of the patient. Patients were
required to be instructed not to take any new medications or to
change the dose regimen of any existing medication (including
over-the-counter products, herbal medications, and complemen-
tary therapies) without first consulting with the investigator. All
changes had to be noted in the corresponding electronic case
report form.
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TABLE E1. Summary table of additional lung function: prebronchodilator and postbronchodilator FVC and FEF at baseline and the end of each study period
Study visit
Prebronchodilator
FVC (L), mean (SD)
Postbronchodilator
FVC (L), mean (SD)
Prebronchodilator FVC (%
predicted), mean (SD)
Prebronchodilator
FEF25-75% (L/s), mean (SD)
Postbronchodilator
FEF25-75% (L/s), mean (SD)
Roflumilast 1
montelukast
(n 5 32)
Placebo 1
montelukast
(n 5 32)
Roflumilast 1
montelukast
(n 5 29)
Placebo 1
montelukast
(n 5 26)
Roflumilast 1
montelukast
(n 5 32)
Placebo 1
montelukast
(n 5 32)
Roflumilast 1
montelukast
(n 5 31)
Placebo 1
montelukast
(n 5 32)
Roflumilast 1
montelukast
(n 5 28)
Placebo 1
montelukast
(n 5 26)
Period 1 Baseline 3.000 (0.906) 3.307 (1.007) 3.226 (0.822) 3.511 (0.981) 91.6 (16.93) 91.6 (16.30) 1.165 (0.726) 1.389 (0.852) 1.621 (0.862) 1.599 (0.743)
Day 28 0.081 (0.253) 0.064 (0.300) 20.120 (—), n 5 1* 0.110 (0.127), n 5 2* 92.9 (15.46) 92.3 (19.62) 0.147 (0.378) 20.002 (0.227) 0.020 (—) 20.175 (0.262)
Period 2 Baseline 3.259 (1.068) 2.942 (0.875) 3.440 (—), n 5 1* 5.340 (—), n 5 3* 90.8 (18.02) 89.5 (15.28) 1.241 (0.680) 1.105 (0.740) 1.870 (—) 2.900 (—)
Day 84 0.172 (0.393) 0.058 (0.312) 20.080 (—), n 5 3* 0.043 (0.196), n 5 3* 96.5 (19.47) 92.1 (16.48) 0.346 (0.478) 0.141 (0.340) 0.280 (—) 20.023 (0.110)
Baseline, Observed value at visit; days 28 and 84, change from baseline.
*Values based on very small patient numbers indicated in the table (1-3 patients).
Day 84 in period 2 is 28 days from baseline.
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TABLE E2. ANCOVA results for change from baseline to week 4 for secondary end points: FVC, prebronchodilator FEF25-75%,
morning PEF measured at clinic visit, and morning PEF measured at home
Parameter
LS mean (SE),
roflumilast 1
montelukast (A)
LS mean (SE),
placebo 1
montelukast (B)
LS mean
difference (SE),
A vs B
P value,
A vs B
Change in FVC (L) 0.12 (0.029), n 5 58 0.06 (0.027), n 5 61 0.06 (0.040) .129
Change in prebronchodilator FEF25-75% (L/s) 0.23 (0.039), n 5 54 0.11 (0.039), n 5 55 0.12 (0.056) .032
Change in morning PEF from clinic measurement (L/min) 15.05 (10.616), n 5 58 7.85 (10.401), n 5 61 7.21 (15.105) .635
Change in morning PEF from home measurement (L/min) 20.85 (3.708), n 5 60 7.23 (3.646), n 5 61 13.62 (5.206) .011
Data are provided as LS means (SEs).
A, Roflumilast (500 mg) plus montelukast (10 mg) once daily; B, placebo plus montelukast (10 mg) once daily.
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TABLE E3. Baseline values and change from baseline in eosinophil and neutrophil numbers (109/L) during periods 1 and 2 by
treatment
Treatment sequence* Baseline
Change from baseline in mean (SD) absolute values
Day 1 Day 28 Day 84 Final visit
Neutrophils (109/L) AB (n 5 32) 4.431 (1.7466) 20.098 (1.7592) 20.401 (2.6141) 20.207 (1.5513) 20.033 (1.6140)
BA (n 5 32) 4.275 (1.6311) 20.332 (1.0603) 0.028 (2.5745) 0.176 (1.3369) 0.011 (1.2952)
Eosinophils (109/L) AB (n 5 32) 0.294 (0.2242) 20.017 (0.1445) 20.027 (0.1316) 20.034 (0.1822) 20.024 (0.1871)
BA (n 5 32) 0.289 (0.2124) 0.015 (0.0966) 20.035 (0.1074) 20.052 (0.1171) 0.009 (0.1157)
A, Roflumilast (500 mg) plus montelukast (10 mg) once daily; B, placebo plus montelukast (10 mg) once daily.
*On day 28, change from baseline in mean absolute values was calculated by using 7 patients in sequence AB and 10 patients in sequence BA.
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TABLE E4. TEAEs
Preferred term
No. (%) of patients
Roflumilast 1 montelukast (n 5 61) Placebo 1 montelukast (n 5 62) Total (n 5 64)
Headache 5 (8.2) 0 5 (7.8)
Influenza 2 (3.3) 2 (3.2) 4 (6.3)
Blood creatinine phosphokinase increased 2 (3.3) 1 (1.6) 3 (4.7)
Bronchitis 0 3 (4.8) 3 (4.7)
Diarrhea 2 (3.3) 1 (1.6) 3 (4.7)
Nasopharyngitis 2 (3.3) 1 (1.6) 3 (4.7)
Viral upper respiratory tract infection 2 (3.3) 2 (3.2) 3 (4.7)
Laryngitis 0 2 (3.2) 2 (3.1)
Nausea 2 (3.3) 0 2 (3.1)
Pain in extremity 1 (1.6) 1 (1.6) 2 (3.1)
Syncope 2 (3.3) 0 2 (3.1)
Upper respiratory tract infection 1 (1.6) 1 (1.6) 2 (3.1)
Data are numbers (percentages) unless otherwise indicated. Patients might have had more than 1 AE.
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TABLE E5. TEAEs by severity and leading to discontinuation of study medication during treatment with roflumilast plus
montelukast and placebo plus montelukast
Roflumilast 1 montelukast
(n 5 61)
Placebo 1 montelukast
(n 5 62) Total (n 5 64)
Events Patients, no. (%) Events Patients, no. (%) Events Patients, no. (%)
Any TEAE 42 28 (45.9) 25 21 (33.9) 67 41 (64.1)
Related 10 8 (13.1) 3 3 (4.8) 13 9 (14.1)
Mild 27 18 (29.5) 15 12 (19.4) 42 24 (37.5)
Moderate 14 9 (14.8) 9 8 (12.9) 23 15 (23.4)
Severe 1 1 (1.6) 1 1 (1.6) 2 2 (3.1)
Leading to discontinuation 1 1 (1.6) 2 2 (3.2) 3 3 (4.7)
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